Replies to post #246901 on Biotech Values

[dewophile]

The efficacy of Nirsevimab is roughly similar to PFE’s maternal RSV vaccine, which has an Aug 2023 PDUFA date (#msg-171260623)

I still cannot figure out why GSK's vaccine had a safety signal for preterm birth and PFE's did not. GSK's maternal vaccine was also a non adjuvenated vaccine targeting prefusion.
If it were me I probably would opt for Nirsevimab over the maternal vaccine until there is a larger safety database for the vaccine (assuming approval)